MENU
MTVA
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION
MetaVia (MTVA) Ownership - Who owns MetaVia?
Details
Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
16.76M
P/E Ratio
N/A
Total Cash
21.67M
Projected Growth
N/A
Total Debt
154K
Revenue
N/A
Risk (Beta)
0.39
Dividend Yield
N/A
Total Cash/Share
2.51
Total Debt/Equity
N/A
Revenue/Share
null USD as % of share price
Fundamentals
MTVA
Capitalization
16.8M
P/E Ratio
N/A
Risk (Beta)
0.39
Dividend Yield
N/A
Total Cash
21.7M
Total Cash/Share
2.51
Total Debt
154K
Total Debt/Equity
N/A
Projected Growth (PEG Ratio)
N/A
Revenue/Share (as % of the share price)
0%
Revenue
0
ROE
N/A
Book Value
13M
P/B Ratio
1.29
Cash Flow
N/A
Earnings
-4.29
Average Daily Volume YTD
N/A
Common Shares Outstanding - Security Level
9K
Current Ratio
2.41
Current Revenue Per Employee
N/A
Dividends Per Share - Security
N/A
EBITDA
-25.46M
Float
N/A
Float - Current
N/A
Gross Income Margin
N/A
Revenue To Assets
-114.20
Shares Held By Institutions
3.78M
Shares Outstanding - Current
8.62M
Total Liabilities
9.19M
Total Volume MTD
N/A
Value
N/A
Gain YTD
-4.187
View a ticker or compare two or three
VS
VS
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information
General Information
a clinical-stage biotechnology company focused on developing novel pharmaceuticals to treat neurodegenerative disorders.
Industry Biotechnology
Profile
Fundamentals
Details